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in the EPO group was matched by Hb and GFR to one control
CKD patient not receiving EPO. The time from when the EPO
and matched control patients had the same GFR value to dialy-
sis was compared. The economic impact of EPO on delaying
dialysis was monetized using published Medicare expenditures
in 2001, adjusted to 2005, at $1204 per member per month
(PMPM) prior to end-stage renal disease (ESRD) and $6020
PMPM for the post-ESRD period, and was calculated as the
PMPM cost difference between the post- and pre-ESRD periods
multiplied by the number of months of delay to dialysis by EPO.
RESULTS: Sixty-eight patients (34 EPO and 34 controls) formed
the study population. Mean age was similar between the two
groups (years; EPO: 75.0 vs. control: 75.3), with a higher pro-
portion of men in the EPO group (68% vs. 44%). The average
time to dialysis was 156 days longer for the EPO group (319 ±
252 vs. 163 ± 151 days, P = 0.003), resulting in cost savings of
$25,044 per patient relative to the control group. CONCLU-
SIONS: This matched cohort analysis suggested that elderly
CKD patients receiving EPO had a longer time to dialysis, thus
reducing medical costs. These ﬁndings need to be further 
validated.
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OBJECTIVE: Patients with CKD typically have progressive loss
of kidney function, eventually leading to anemia. Anemia of
pCKD may contribute to worsening of health, resulting in higher
costs to employers. This analysis quantiﬁes the economic burden
of untreated anemia in pCKD patients from an employer’s per-
spective. METHODS: A retrospective analysis was conducted
using anonymous health and disability claims from 31 U.S.
employers between January 1998 and January 2005 from
approximately 5 million individuals. A total of 7258 pCKD
patients with at least two CKD claims less than 90 days apart
prior to dialysis, not receiving anemia therapy with erythropoi-
etic-stimulating agents and with no history of organ transplant
were identiﬁed. Of these, 1534 (21%) with at least 2 anemia
ICD-9 diagnosis claims were classiﬁed as anemic. The anemia
period was from the ﬁrst anemia claim to disenrollment, organ
transplant, or study end. The remaining 5724 patients provided
the non-anemia reference period. To isolate costs speciﬁc to
anemia, multivariate regression analyses were conducted to
control for liver cirrhosis, hypertension, chemotherapy, Charlson
Comorbidity Index, age, sex, health plan, and region. Employ-
ers’ costs comprised direct medical/indirect productivity (short-
and long-term disability, sick leave). RESULTS: Univariate and
multivariate analyses indicated that untreated anemia was asso-
ciated with statistically signiﬁcant increases in direct and indirect
costs. The univariate incremental monthly direct and indirect
costs of untreated anemia were $1344 ($2401 untreated anemic
vs. $1057 non-anemic, p < 0.001), a 2.3 :1 cost ratio, and $271
($620 vs. $349, p < 0.001), a 1.8 :1 cost ratio. Multivariate
analyses conﬁrmed that incremental monthly direct and indirect
costs for untreated anemia remained signiﬁcant at $855 (p <
0.001), a 1.8 :1 cost ratio, and $164 (p < 0.001), a 1.5 :1 cost
ratio. CONCLUSIONS: Untreated anemia in pCKD patients was
associated with signiﬁcantly higher direct and indirect costs to
employers. Studies are needed to evaluate cost-effectiveness of
treating anemia of pCKD.
UR3
FACTORS ASSOCIATED WITH CARE SEEKING FOR
OVERACTIVE BLADDER SYMPTOMS
Nichol MB1, Brubaker L2, Fanning K3, Hussein M4, Becker RV4,
Benner JS4
1University of Southern California, Los Angeles, CA, USA, 2Loyola
University Medical Center, Maywood, IL, USA, 3Vendanta Associates
Inc, Wilmington, NC, USA, 4ValueMedics Research, LLC, Falls Church,
VA, USA
OBJECTIVE: To identify factors associated with the decision to
seek care from a health professional for overactive bladder
(OAB) symptoms. METHODS: A cross-sectional survey was
conducted to identify US adults with symptoms of OAB. The
sampling frame was selected from an existing consumer panel of
600,000 households. A 2-stage sampling scheme was used to
obtain the target subsample (n = 260,000) of individuals repre-
sentative of US adults for age, sex, geographic area, household
size, and urban versus rural location. The survey used the Over-
active Bladder-Validated 8 (OAB-V8) instrument (total score
ranging from 0–40) and additional questions probing health
care-seeking behavior and treatment patterns. Only subjects
scoring ≥8 (ie, probable OAB) on the OAB-V8 were included in
this analysis. Classiﬁcation and regression tree analysis was used
to identify the demographic characteristics and symptoms asso-
ciated with consulting a health care professional (ie, physician
or nurse). RESULTS: Of the 162,906 subjects returning the
survey (63% response rate), 43,252 (27%) had a score ≥8. Of
these, 19,761 (46%) reported that they had consulted a health
professional regarding their bladder symptoms. Sex, “urine loss
associated with a strong desire to urinate” (UL) and “frequent
urination-daytime hours” (frequency) were most strongly asso-
ciated with consulting. The full tree model, which consisted of 9
variables and 2835 nodes, produced a misclassiﬁcation rate of
29%. A limited tree with only sex, UL, frequency, and 6 nodes
produced a 39% misclassiﬁcation rate. CONCLUSIONS: A
number of characteristics inﬂuenced the decision to seek health-
care for bladder symptoms, with the 3 strongest characteristics
being: 1). female gender; 2). a bother rating of “a little bit” or
more from UL; and 3). a bother rating of “some” or more from
frequency. Additional research is needed to identify other factors
that contribute to healthcare-seeking behaviors.
UR4
THE COST-EFFECTIVENESS OF VARIOUS TREATMENT
STRATEGIES FOR ABNORMAL UTERINE BLEEDING
Trussell J1, Liu Z2, Guo A3, Doan QV2, Dubois RW2, Borenstein J4,
Singh RH5, Blumenthal PD5
1Princeton University, Princeton, NJ, USA, 2Cerner Health Insights,
Beverly Hills, CA, USA, 3Berlex Laboratories, Montville, NJ, USA,
4UCLA, Los Angeles, CA, USA, 5Johns Hopkins University, Baltimore,
MD, USA
OBJECTIVES: Approximately 30% of women of reproductive
age complain of abnormal uterine bleeding (AUB). The objec-
tives of this study were to compare the cost-effectiveness of treat-
ment strategies with the levonorgestrel-releasing intrauterine
system (LNG-IUS), combined oral contraception pills (OCs), or
surgical treatment (endometrial ablation or hysterectomy) for
managing AUB in women who do not desire more children.
METHODS: A Markov model was constructed from the per-
spective of payers over a 5-year period with a 1-year cycle length.
Model inputs were obtained from a comprehensive literature
review. Treatment costs included: drug, device, hospitalization,
